Physicians
PTC’s $211M bid wins Sangamo auction, teeing up ‘special opportunity’ to enter Fabry market
- PTC Therapeutics has struck a deal to buy Sangamo Therapeutics’ Fabry disease program for $111 million upfront, outbidding Astellas and TerSera Therapeutics for the near-approval gene therapy. Sangamo, selling assets as